Gene-editing startup Metagenomi and cancer specialist NeOnc Technologies have announced the terms of their initial public offerings, in another sign that investor interest in biotech is growing.
Emeryville, California-based Metagenomi aims to raise around $87 million through the offer of 6.25 million shares priced between $15 and $17 each, which would value the company at around $640 million if completed. It plans to trade on the Nasdaq under the MGX ticker.
